Government of Hong Kong   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Hong Kong Hong Kong (1997)

Organization Overview

First Clinical Trial
1999
NCT00563927
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hong Kong Association of Youth Department | Hospital Authority | Hospital Authority, Hong Kong | Innovation and Technology Commission, Hong Kong | The Research Fund for the Control of Infectious Diseases of the Food and Health Bureau, the Government of the Hong Kong SAR

Active Ingredients

Drugs in Phase 4 Trials (10)

amlodipine (norvasc) (1 trial)

inactivated influenza vaccine (3 trials)

indapamide (lozol) (1 trial)

irbesartan (avapro) (1 trial)

jing fang bai du san (1 trial)

methyldopa (aldomet) (1 trial)

metoprolol (lopressor) (1 trial)

nifedipine (procardia) (1 trial)

ramipril (altace) (1 trial)

ying qiao san (1 trial)

Drugs in Phase 3 Trials (9)

acetaminophen (tylenol) (2 trials)

chlorambucil (Leukeran) (1 trial)

gabapentin (neurontin) (2 trials)

ketorolac (acuvail) (1 trial)

methoxyflurane (penthrane) (1 trial)

mycophenolate (CellCept) (3 trials)

prednisone (meticorten) (2 trials)

tacrolimus (prograf) (1 trial)

tramadol (Ultram) (1 trial)

Drugs in Phase 2 Trials (7)

carboplatin (paraplatin) (1 trial)

gemcitabine (gemzar) (1 trial)

huangkui (1 trial)

interferon beta-1b (betaseron) (2 trials)

lopinavir (Kaletra) (2 trials)

ribavirin (virazole) (3 trials)

ritonavir (Norvir) (2 trials)

Drugs in Other Trials (33)

adefovir dipivoxil (hepsera) (1 trial)

alfuzosin (uroxatral) (1 trial)

azithromycin (zithromax) (1 trial)

basiliximab (Simulect) (1 trial)

capecitabine (xeloda) (1 trial)

celecoxib (celebrex) (1 trial)

chlordiazepoxide (librium) (1 trial)

cisplatin (platinol) (3 trials)

clidinium (quarzan) (1 trial)

cyclosporine (sandimmune) (1 trial)

darbepoetin alfa (aranesp) (1 trial)

diclofenac (voltaren) (1 trial)

doxazosin (cardura) (1 trial)

epoetin (Epogen) (1 trial)

esomeprazole (nexium) (1 trial)

fluorouracil (efudex) (3 trials)

gr270774 (1 trial)

lamivudine (epivir) (2 trials)

l-glutamine (1 trial)

midazolam (versed) (1 trial)

naltrexone (revia) (1 trial)

nicotine (nicorette) (1 trial)

rabeprazole (pariet) (2 trials)

resveratrol (1 trial)

risperidone (risperdal) (1 trial)

saw palmetto (1 trial)

sen miao san (1 trial)

sitagliptin (januvia) (1 trial)

tegaserod (zelnorm) (2 trials)

terazosin (hytrin) (1 trial)

tivantinib (1 trial)

vardenafil (levitra) (1 trial)

zoledronic acid (zometa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Constipation (Phase 2)

Coronavirus Infections (Phase 2)

Diabetes Mellitus (Phase 4)

Emergencies (Phase 3)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 3)

Hypertension (Phase 4)

Infections (Phase 4)

Influenza, Human (Phase 4)

Kidney Diseases (Phase 3)

Lung Neoplasms (Phase 2)

Lupus Nephritis (Phase 3)

Muscle Weakness (Phase 3)

Nephritis (Phase 3)

Paresis (Phase 3)

Respiratory Tract Infections (Phase 4)

Rupture (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 59